Nautilus Biotechnology, Inc.
NASDAQ:NAUTBiotechnology
Healthcare
$2.43 +2.06%
+$0.05 today
- Market cap
- $309.51M
- Beta
- 0.75
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$0.45
52W Low $0.62High $4.31
Volume 4.55M
Average 0.40M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$66.84M
FY 2025 · Annual
Net Income
-$59.00M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 2.84M | 3.42M | 5.71M | 6.35M | 6.47M |
| Gross Profit | (2.84M) | (3.42M) | (5.71M) | (6.35M) | (6.47M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 26.51M | 36.46M | 47.25M | 50.48M | 41.11M |
| Selling, General & Admin | 21.15M | 23.75M | 28.9M | 31M | 25.73M |
| Operating Expenses | 47.66M | 60.2M | 70.45M | 75.12M | 60.37M |
| Depreciation & Amortization | 2.84M | 3.42M | 1.85M | 6.35M | 6.47M |
| EBITDA | (47.47M) | (54.51M) | (61.83M) | (64.43M) | (52.54M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (50.5M) | (63.62M) | (76.15M) | (81.48M) | (66.84M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 329K | 5.82M | 12.55M | 10.78M | 7.87M |
| Interest Expense | 0 | 5.82M | 0 | 0 | 0 |
| Other Income / Expenses | 183K | 5.69M | 12.48M | 10.7M | 7.84M |
| Income Before Tax | (50.32M) | (57.92M) | (63.68M) | (70.78M) | (59M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (50.32M) | (57.92M) | (63.68M) | (70.78M) | (59M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.60) | (0.46) | (0.51) | (0.56) | (0.47) |
| EPS (Diluted) | (0.60) | (0.46) | (0.51) | (0.56) | (0.47) |
| 84.46M | 124.59M | 124.92M | 125.43M | 126.26M | |
| 84.46M | 124.59M | 124.92M | 125.43M | 126.26M |
NAUT Earnings Waterfall · TTM
NASDAQ:NAUT · Revenue to Net Income
Key Ratios
EPS$-0.46
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-4.1
P/S Ratio0.0
Analysis
$0 of revenue converted into -$57.1M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.46, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13D/A | SC 13D/A filing | Nov 3, 2026 | |
| 10-Q | Quarterly report | Oct 27, 2026 | |
| 8-K | Current report | Oct 27, 2026 | |
| EFFECT | EFFECT filing | Sep 18, 2026 | |
| 424B5 | 424B5 filing | Sep 18, 2026 |
How much revenue does NAUT generate?
Nautilus Biotechnology, Inc. (NAUT) reported $0.00 of revenue in fiscal 2025.
Is NAUT profitable?
Nautilus Biotechnology, Inc. (NAUT) reported -$59.00M of net income.
Continue the stock analysis
Jump to another research area for this company.